Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images)
Novartis scuttles trial for program lauded by Vas Narasimhan as emerging transplant drug star
A program touted by Novartis CEO Vas Narasimhan as a near-slam dunk has flopped a Phase IIb study, leading the Swiss biopharma to discontinue the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
